Robert Brennan, MD
Infectious Disease · Lynchburg, VANPI 1659355170
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $135 of the $161 with a category attached, or 84.2%. 7 manufacturers reported payments, led by Amgen at 19.0% of the total. Reporting peaked in 2020 at $75 and has fallen 61.2% since, to $29 in 2025. That places this record below the midpoint for infectious disease clinicians in VA, where the typical reported total is $169.
Across 10 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$30
- Insmed, Inc.$29
- AstraZeneca$27
- Merck$25
- Genentech USA, Inc.$18
- AbbVie$17
- plus $14 from 1 others
Across 175 payments — averaging $4214.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$509K
- Janssen Research & Development, LLC$147K
- Sanofi Pasteur Inc.$39K
- Chiesi USA, Inc.$26K
- GSK$17K
What the payments were for
- Food & beverage$13584%
- Education$2516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $30 |
| Insmed, Inc. | 1 | $29 |
| AstraZeneca | 2 | $27 |
| Merck | 2 | $25 |
| Genentech USA, Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
How this compares
$161 in reported general payments places this provider in the 45th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 49 | $198,943 |
| DescovyEmtricitabine/Tenofov Alafenam | 28 | $65,490 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $59,808 |
| JulucaDolutegravir/Rilpivirine | 15 | $58,753 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $53,648 |
| TivicayDolutegravir Sodium | 21 | $47,471 |
| Daptomycin | 21 | $23,487 |
| ErtapenemErtapenem Sodium | 14 | $4,855 |
| CeftriaxoneCeftriaxone Sodium | 32 | $2,949 |
| Ampicillin Sodium | 11 | $1,791 |
| Efavirenz | 11 | $749 |
| Sodium Chloride0.9 % Sodium Chloride | 51 | $301 |
| Ciprofloxacin Hcl | 15 | $234 |
| Amoxicillin | 14 | $189 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Lynchburg
- Christopher BettacchiMarion$243K
- Stephen WeinrothFairfax$157K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
- Valerie RiddleBumpass$83K
- Edward OldfieldNorfolk$81K
- William FurlongArlington$68K
- Frederick HaydenCharlottesville$61K
- David WheelerAnnandale$49K
- Amy MathersCharlottesville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.